The TG01 IND application by Circio’s partner IOVaxis Therapeutics has been approved by the Chinese regulatory authorities
· The IND application filed by partner IOVaxis Therapeutics to initiate TG01 clinical development in China was approved by the Chinese NMPA on 1 March 2024 · Following IND approval, IOVaxis has an option to exercise an exclusive license for Circio’s TG mutant RAS cancer vaccine program for Greater China and Singapore Oslo, Norway 4 March 2024 – Circio Holding ASA (OSE: CRNA) announces that the TG01 investigational new drug (IND) application filed by partner IOVaxis Therapeutics of Nantong, China, has been approved by the Chinese National Medical Products Administration (NMPA).